{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":3,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":53,"n_cols":5,"rows_kept":53,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[9,2,9,3],[9,4,9,5],[10,2,10,3],[10,4,10,5],[11,2,11,3],[11,4,11,5],[12,2,12,3],[13,2,13,3],[14,2,14,3],[15,2,15,3],[16,2,16,3],[17,2,17,3],[21,2,21,3],[22,2,22,3],[24,2,24,3],[24,4,24,5],[25,2,25,3],[25,4,25,5],[26,2,26,3],[27,2,27,3],[34,2,34,3],[35,2,35,3],[36,2,36,3],[37,2,37,3],[39,2,39,3],[40,2,40,3],[44,2,44,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNICAMPANIASUN0087712"]
[null,null,"Autore",null,"Pulci, Luigi"]
[null,null,"Titolo",null,"Il Morgante di Luigi Pulci, nobil' fiorentino. Nuouamente corretto, e ristampato con licenzia de superiori"]
[null,null,"Pubbl/distr/stampa",null,"[16], 390, [2] p. ; 4°"]
[null,null,"Edizione",null,"[In Fiorenza : nella Stamperia di Bartolomeo Sermartelli, 1574 (In Fiorenza : nella Stamperia di Bartolomeo Sermartelli, 1574)]"]
[null,null,"Descrizione fisica",null,"Segnatura: †⁸ A-2A⁸ 2B⁴"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,"2.","Record Nr.",null,"UNISALENTO991000527059707536"]
[null,null,"Autore",null,"Savoca, Giuseppe"]
[null,null,"Titolo",null,"Concordanze dell'Isotteo e delle elegie romane di Gabriele D'Annunzio : testi, concordanze, liste di frequenza, indici / Giuseppe Savoca, Alida D'Aquino"]
[null,null,"Pubbl/distr/stampa",null,"Firenze : L. S. Olschki, 1990"]
[null,null,"ISBN",null,"8822238117"]
[null,null,"Descrizione fisica",null,"XLIV, 310 p. ; 24 cm"]
[null,null,"Collana",null,"Strumenti di lessicografia letteraria italiana ; 8"]
[null,null,"Disciplina",null,"851.912"]
[null,null,"Soggetti",null,"D'Annunzio, Gabriele. Elegie romane Concordanze"]
[{"$nulls":4},"D'Annunzio, Gabriele. Isotteo Concordanze"]
[{"$nulls":4},"D'Annunzio, Gabriele. Elegie romane Concordanze"]
[{"$nulls":4},"D'Annunzio, Gabriele. Isotteo Concordanze"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,"3.","Record Nr.",null,"UNINA9910960560903321"]
[null,null,"Titolo",null,"Vaccines for the 21st century : a tool for decisionmaking / / Kathleen R. Stratton, Jane S. Durch, and Robert S. Lawrence, editors ; Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine"]
[null,null,"Pubbl/distr/stampa",null,"Washington, D.C., : National Academy Press, c2000"]
[null,null,"ISBN",null,"9786610191840"]
[{"$nulls":4},"9780309174985"]
[{"$nulls":4},"0309174988"]
[{"$nulls":4},"9781280191848"]
[{"$nulls":4},"1280191848"]
[{"$nulls":4},"9780309564434"]
[{"$nulls":4},"0309564433"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (472 p.)"]
[null,null,"Disciplina",null,"615/.372/072073"]
[null,null,"Soggetti",null,"Vaccines - Research - United States - Planning"]
[{"$nulls":4},"Immunization - Research - United States - Planning"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Bibliographic Level Mode of Issuance: Monograph"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Vaccines for the 21st Century -- Copyright -- Acknowledgments -- Contents -- Executive Summary -- THE ANALYTIC FRAMEWORK -- ETHICAL ISSUES -- RESULTS -- OBSERVATIONS -- 1 Introduction -- CONSIDERATIONS RELATED TO THE MODEL AND THE STUDY -- ORGANIZATION OF THE REPORT -- Charge to the Committee -- Committee Membership and Meetings -- Organization of the Report -- 2 Progress in Vaccine Development -- PRIORITIES OF THE IOM COMMITTEE IN 1985 -- LITIGATION AS A BARRIER TO VACCINE DEVELOPMENT -- Immunization of Pregnant Women -- A CASE STUDY OF SUCCESS -- Disease Burden -- Polio Vaccine Development -- Advantages of Evolving Vaccine Strategies -- ADVANCES IN BIOTECHNOLOGY AND MOLECULAR IMMUNOLOGY AND NEW OPPORTUNITIES FOR VACCINES -- Fundamental Understanding of Helper T Cells for Antibody Versus CMI Responses, and for Cytotoxicity -- Major Advances in Mucosal Immunity -- Mucosal Immune System Organization -- Molecular Aspects of Virulence and Design of Recombinant Protein Vaccines -- Novel Vaccine Delivery Systems -- "]
[{"$nulls":4},"Recent Advances in Development of Novel Adjuvants -- Scientific Rationale for Vaccines against Autoimmune Diseases -- Immune Tolerance Induction -- Immune Deviation -- Receptor-Centered Regulation -- Targeting Cytokines or Their Receptors -- Viral Vectors in Autoimmune Therapy -- Preventive Vaccines for Autoimmune Diseases -- 3 Considerations of Candidate Vaccines -- EXCLUSION CRITERIA -- Insufficient Basic Science Information -- Existence of Appropriate Prevention Interventions -- International Burden of Disease -- ADDITIONAL CONSIDERATIONS FOR INCLUSION -- Therapeutic Vaccines -- Programmatic Considerations -- Delivery of Vaccines to Children -- Delivery of Vaccines to Adults -- Delivery of Vaccines to Pregnant Women -- 4 Overview of Analytic Approach and Results -- A COST-EFFECTIVENESS APPROACH."]
[{"$nulls":4},"Reasons for Using Cost-Effectiveness Analysis -- Limits of Cost-Effectiveness Analysis -- Ethical Issues -- Analytic Perspectives -- Time Horizon and Discounting -- MODEL OVERVIEW -- Health Benefits: The Denominator -- Quality Adjustments: Weighting -- Morbidity Scenarios -- Quality Adjustments for Average Population Health States -- Disease Incidence and Death Rates -- Time Intervals -- QALYs Gained with Vaccine Use -- Costs: The Numerator -- Cost of Research and Development -- Cost of Vaccine Use -- Health Care Costs -- Vaccine Efficacy and Utilization -- Cost-Effectiveness Ratios -- Exclusions from the Analysis -- EXAMPLES: HYPOTHETICAL VACCINE X -- Target Population -- Program Considerations -- Disease Severity -- Discounting -- An Idealized Scenario -- Summary -- RESULTS -- Challenges -- 5 Review of the Analytic Model -- UNIT OF ANALYSIS -- IMPLEMENTING THE ANALYSIS -- Basic Model -- Performing the Analysis -- CALCULATION OF HEALTH BENEFITS -- Quality-Adjusted Life Years -- Quality-Adjustment Weights Based on the Health Utilities Index -- Steps in the Calculation of Anticipated Health Benefits from Vaccine Use -- Develop Morbidity Scenarios -- Calculate Quality-Adjustment Weights -- Calculate Discounted Quality-Adjusted Life Expectancies -- Establish Age-Specific Incidence and Death Rates -- Calculate Time Intervals for Discounting Future Health Benefits -- Calculate Condition-Related Life Expectancies -- Adjust for the Underlying Health Status of the Population -- Calculate Discounted QALYs for Each Health State -- Calculate Total QALYs Gained with Vaccine Use -- COST FACTORS -- Vaccine Development -- Vaccine Use -- Cost of Care -- VACCINE EFFICACY AND UTILIZATION -- COST-EFFECTIVENESS RATIOS -- 6 Ethical Considerations and Caveats -- ETHICAL AND VALUE JUDGMENTS BUILT INTO THE MODEL -- All QALYs Count Equally."]
[{"$nulls":4},"Years of Life at Different Ages Are Weighted by Quality -- The Value of Life Extension with and without Disabilities -- Discount Rates for Costs and Benefits -- Which Benefits and Costs Should Be Counted in the Prioritization Process? -- CONSIDERATIONS OF JUSTICE -- Small Benefits to Many Versus Large Benefits to a Few -- What Priority Should Be Given to the Worst-Off or Sickest? -- Fair Chances Versus Best Outcomes -- CONCLUSION -- 7 Observations -- THE FUNDING OF RESEARCH -- NEGLECTED OPPORTUNITIES FOR VACCINE R&amp -- D -- International Considerations -- Small Target Populations -- Liability Concerns -- QUALITATIVE JUDGMENTS -- VACCINE PROGRAM CONCERNS -- References -- APPENDIX 1 Borrelia burgdorferi -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 2 Chlamydia -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios: "]
[{"$nulls":4},"Women -- Disease Scenarios: Men -- Disease Scenarios: Infants -- COSTS INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 3 Coccidioides immitis -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 4 Cytomegalovirus -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 5 Enterotoxigenic E. coli -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios."]
[{"$nulls":4},"COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 6 Epstein-Barr Virus -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 7 Helicobacter pylori -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 8 Hepatitis C -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 9 Herpes Simplex Virus -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- Oral Infections -- Ocular Infections -- Central Nervous System Infections -- Genital Infections -- Neonatal Infections -- COST INCURRED BY DISEASE -- Oral and Ocular Infections -- Central Nervous System Infections -- Genital Infections -- Neonatal Infections -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 10 Histoplasma capsulatum -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 11 Human Papillomavirus -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT."]
[{"$nulls":4},"VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 12 Influenza A and B -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 13 Insulin-Dependent Diabetes Mellitus -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 14 Melanoma -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS "]
[{"$nulls":4},"-- READING LIST -- APPENDIX 15 Multiple Sclerosis -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 16 Mycobacterium tuberculosis -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 17 Neisseria gonorrhea -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 18 Neisseria meningitidis B -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT."]
[{"$nulls":4},"VACCINE PROGRAM CONSIDERATIONS."]